Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2018

14.12.2016 | Original Research

Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience

verfasst von: Tarek Assi, Elie El Rassy, Aline Khazzaka, Tania Moussa, Tony Ibrahim, Clarisse Kattan, Fadi El Karak, Fadi Farhat, Marwan Ghosn, Joseph Kattan

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The epidemiology of gastric cancer in the Middle East has never been described. Therefore, the characteristics of gastric cancer in the Lebanese population will be reported in this study.

Patients and Methods

A retrospective study that included all patients diagnosed with gastric cancer at Hotel Dieu de France University Hospital in Beirut, Lebanon between 2010 and 2016 was conducted. All eligible patients were reviewed for demographic and epidemiologic analysis.

Results

The study included 123 patients diagnosed with gastric cancer. The median age at diagnosis was 59 years (range 15–72 years), and the median ECOG performance status was 2 (range 1–4). Most patients were metastatic at diagnosis (52.8%), and diffuse pathology type was predominant (39%). HER2 was positive in 16.2% and correlated with the occurrence of hepatic metastasis (p = 0.048). The HER2 status did not differ significantly between the histological subtypes, the site of the tumor, the stage of the gastric cancer at diagnosis, and the recurrence of cancer (p > 0.05).

Conclusion

Gastric cancer in the Lebanese population is characterized by aggressive features such as advanced stage at diagnosis, high prevalence of diffuse type histology, and HER2 positivity.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
2.
Zurück zum Zitat Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125(3):666–73.CrossRefPubMed Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125(3):666–73.CrossRefPubMed
3.
Zurück zum Zitat Boku N. HER2-positive gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2014 Jan;17(1):1–12. Boku N. HER2-positive gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2014 Jan;17(1):1–12.
5.
Zurück zum Zitat Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2009;18(7):1945–52.CrossRef Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2009;18(7):1945–52.CrossRef
6.
Zurück zum Zitat Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer Oxf Engl 1990. 2014;50(7):1330–44. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer Oxf Engl 1990. 2014;50(7):1330–44.
7.
Zurück zum Zitat Mabula JB, Mchembe MD, Koy M, Chalya PL, Massaga F, Rambau PF, et al. Gastric cancer at a university teaching hospital in northwestern Tanzania: a retrospective review of 232 cases. World J SurgOncol. 2012;10:257.CrossRef Mabula JB, Mchembe MD, Koy M, Chalya PL, Massaga F, Rambau PF, et al. Gastric cancer at a university teaching hospital in northwestern Tanzania: a retrospective review of 232 cases. World J SurgOncol. 2012;10:257.CrossRef
8.
Zurück zum Zitat Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013;8:76.CrossRefPubMedPubMedCentral Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013;8:76.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer. 2012;130(12):2845–56.CrossRefPubMed Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer. 2012;130(12):2845–56.CrossRefPubMed
10.
Zurück zum Zitat Mohammed AA, Al-Zahrani AS, El-Kashif AT. P0022 clinicopathological features of gastric cancer: a single-centre experience. Eur J Cancer. 2014;50(Supplement 4):e15.CrossRef Mohammed AA, Al-Zahrani AS, El-Kashif AT. P0022 clinicopathological features of gastric cancer: a single-centre experience. Eur J Cancer. 2014;50(Supplement 4):e15.CrossRef
11.
Zurück zum Zitat El-Gendi S, Talaat I, Abdel-Hadi M. HER-2/Neu status in gastric carcinomas in a series of Egyptian patients and its relation to Ki-67 expression. Open Journal of Pathology. 2015;5(04):101.CrossRef El-Gendi S, Talaat I, Abdel-Hadi M. HER-2/Neu status in gastric carcinomas in a series of Egyptian patients and its relation to Ki-67 expression. Open Journal of Pathology. 2015;5(04):101.CrossRef
12.
Zurück zum Zitat Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2015;18(4):691–7. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2015;18(4):691–7.
13.
Zurück zum Zitat Van Cutsem E, Bang Y-J, Feng-Yi F, Xu JM, Lee K-W, Jiao S-C, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2015;18(3):476–84. Van Cutsem E, Bang Y-J, Feng-Yi F, Xu JM, Lee K-W, Jiao S-C, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2015;18(3):476–84.
14.
Zurück zum Zitat Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(9):2360–4.CrossRef Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(9):2360–4.CrossRef
15.
Zurück zum Zitat Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2014;17(1):34–42. Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2014;17(1):34–42.
16.
Zurück zum Zitat Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMed Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMed
17.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed
18.
Zurück zum Zitat Diaz-Nieto R, Orti-Rodríguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013;9:CD008415. Diaz-Nieto R, Orti-Rodríguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013;9:CD008415.
19.
Zurück zum Zitat Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(18):2903–9.CrossRef Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(18):2903–9.CrossRef
20.
Zurück zum Zitat Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 1997;8(2):163–8.CrossRef Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 1997;8(2):163–8.CrossRef
21.
Zurück zum Zitat Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(11):2850–4.CrossRef Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(11):2850–4.CrossRef
22.
Zurück zum Zitat Monti M, Foca F, Casadei Gardini A, Valgiusti M, Frassineti GL, Amadori D. Retrospective analysis on the management of metastatic gastric cancer patients. A mono-institutional experience. What happens in clinical practice? Tumori. 2013;99(5):583–8.PubMed Monti M, Foca F, Casadei Gardini A, Valgiusti M, Frassineti GL, Amadori D. Retrospective analysis on the management of metastatic gastric cancer patients. A mono-institutional experience. What happens in clinical practice? Tumori. 2013;99(5):583–8.PubMed
23.
Zurück zum Zitat Elsing C, Herrmann C, Hannig CV, Stremmel W, Jäger D, Herrmann T. Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients. Oncology. 2013;85(5):262–8.CrossRefPubMed Elsing C, Herrmann C, Hannig CV, Stremmel W, Jäger D, Herrmann T. Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients. Oncology. 2013;85(5):262–8.CrossRefPubMed
24.
Zurück zum Zitat Iacovelli R, Pietrantonio F, Farcomeni A, Maggi C, Palazzo A, Ricchini F, et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One. 2014;9(9):e108940.CrossRefPubMedPubMedCentral Iacovelli R, Pietrantonio F, Farcomeni A, Maggi C, Palazzo A, Ricchini F, et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One. 2014;9(9):e108940.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Assi T, Rassy EE, Tabchi S, Ibrahim T, Moussa T, Chebib R, et al. Treatment of cancer patients in their last month of life: aimless chemotherapy. Support Care Cancer. 2015;21:1–6. Assi T, Rassy EE, Tabchi S, Ibrahim T, Moussa T, Chebib R, et al. Treatment of cancer patients in their last month of life: aimless chemotherapy. Support Care Cancer. 2015;21:1–6.
Metadaten
Titel
Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience
verfasst von
Tarek Assi
Elie El Rassy
Aline Khazzaka
Tania Moussa
Tony Ibrahim
Clarisse Kattan
Fadi El Karak
Fadi Farhat
Marwan Ghosn
Joseph Kattan
Publikationsdatum
14.12.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2018
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9903-8

Weitere Artikel der Ausgabe 1/2018

Journal of Gastrointestinal Cancer 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.